ADVERTISEMENT
ADVERTISEMENT

Proteintech Acquires ChromoTek, Expanding its Next Generation Antibody Tools

Proteintech, the benchmark in antibodies, today   announces  the acquisition of ChromoTek, a manufacturer of Camelid, single-domain antibodies, also known as nanobodies. 

Proteintech Group

ChromoTek is the market leader in nanobodies — high-performance recombinant reagents used for breakthrough research discoveries.  The combined companies will better address the industry’s growing opportunities and challenges in single cell analysis, super resolution imaging, and multiplex assays.  

“Our fit-for-purpose nanobody-based tools perfectly complement the comprehensive antibody coverage of the proteome that Proteintech offers,” said Dr. Marion Jung, CEO of ChromoTek.  “It is exciting to be working together with a company that shares our common values in reproducibility and quality for the benefit of research and beyond.”          

Dr. Jason Li, CEO of Proteintech said, “This new partnership will deliver considerable value to the market.  With global manufacturing across three continents, not only will we serve the research market better, but we’ll also deeply impact translational science and therapeutic applications.” 

ADVERTISEMENT